Advertisement

Annals of Surgical Oncology

, 10:910 | Cite as

Telomerase Inhibition Using Azidothymidine in the HT-29 Colon Cancer Cell Line

  • Tommy Brown
  • Elin Sigurdson
  • Andre Rogatko
  • Dominique Broccoli
Original Articles

Abstract

Background: We investigated the effects of telomerase inhibition by using the reverse transcriptase inhibitor azidothymidine (AZT) in the human colorectal cancer cell line HT-29 in the presence and absence of 5-fluorouracil (5-FU).

Methods: HT-29 cells were cultured in the presence of AZT. Telomerase activity was measured by using the telomerase repeat amplification protocol. Telomere length was determined by Southern analysis. The colorimetric microtiter assay was performed to determine the cytotoxic effects of AZT, alone and in combination with 5-FU.

Results: The presence of 3′-azido-3′-deoxythymidine triphosphate (AZT-TP) effectively inhibited telomerase extracted from HT-29 cells. HT-29 cells cultured with 125 μM of AZT underwent fewer total population doublings over 91 days. Southern analysis revealed that telomere attrition occurred within this period. Exposure to 125 μM of AZT resulted in slightly reduced viability (10%) of HT-29 cells. However, the presence of AZT increased 5-FU cytotoxicity, suggesting that the effects of these two drugs are synergistic.

Conclusions: The data are consistent with telomerase inhibition having growth-inhibitory effects in addition to those predicted to accompany loss of telomere function. Further studies using specific small-molecule inhibitors will confirm whether the growth-inhibitory and 5-FU–sensitivity effects seen here are a direct result of telomerase inhibition.

Key Words

Telomerase AZT HT-29 colon cancer cell line Telomere 

REFERENCES

  1. 1.
    Olovnikov AM. A theory of marginotomy. J Theor Biol 1973;41:181–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Collins K. Mammalian telomeres and telomerase. Curr Opin Cell Biol 2000;12:378–83.CrossRefPubMedGoogle Scholar
  3. 3.
    Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang X, Mar V, Zhou W, Harrington L, Robinson M. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999;13:2388–99.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Stewart SA, Hahn WC, O’Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2002;99:12606–11.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Artandi SE, Alson S, Tietze MK, et al. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci U S A 2002;99:8191–6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824–42.CrossRefPubMedGoogle Scholar
  10. 10.
    O’Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996;16:53–65.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kelland LR. Telomerase inhibitors: targeting the vulnerable end of cancer? Anticancer Drugs 2000;11:503–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Falcone A, Danesi R, Dargenio F, et al. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 1996;14:729–36.CrossRefPubMedGoogle Scholar
  14. 14.
    Posner MR, Darnowski JW, Weitberg AB, et al. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer 1992;70:2929–34.CrossRefPubMedGoogle Scholar
  15. 15.
    van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997;385:740–3.CrossRefPubMedGoogle Scholar
  16. 16.
    Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A 1995;92:9082–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ludérus MEE, van Steensel B, Chong L, Sibon OCM, Cremers FFM, de Lange T. Structure, subnuclear distribution, and nuclear matrix association of the mammalian telomeric complex. J Cell Biol 1996;135:867–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Broccoli D, Godley LA, Donehower LA, Varmus HE, de Lange T. Telomerase activation in mouse mammary tumors: lack of telomere shortening and evidence for regulation of telomerase with RNA cell proliferation. Mol Cell Biol 1996;16:3765–72.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rockhold FW, Goldberg MR. An approach to the assessment of therapeutic drug interactions with fixed combination drug products. J Biopharm Stat 1996;6:231–40.CrossRefPubMedGoogle Scholar
  21. 21.
    Longford N. Random Coefficient Models. Oxford: Clarendon, 1993.Google Scholar
  22. 22.
    Gonzalez-Suarez E, Samper E, Ramirez A, et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 2001;20:2619–30.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Biroccio A, Gabellini C, Amodei S, et al. Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells. Mol Pharmacol 2003;63:632–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Tentori L, Portarena I, Barbarino M, et al. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor. Mol Pharmacol 2003;63:192–202.CrossRefPubMedGoogle Scholar
  25. 25.
    Folini M, De Marco C, Orlandi L, Daidone MG, Zaffaroni N. Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. Eur J Cancer 2000;36:2137–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Groschel B, Cinatl J, Cinatl J Jr. Viral and cellular factors for resistance against antiretroviral agents. Intervirology 1997;40:400–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Chiu DT, Duesberg PH. The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy. Genetica 1995;95:103–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Jacobsson B, Britton S, He Q, Karlsson A, Eriksson S. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res Hum Retroviruses 1995;11:805–11.CrossRefPubMedGoogle Scholar
  29. 29.
    Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417–22.CrossRefPubMedGoogle Scholar
  30. 30.
    Damm K, Hemmann U, Garin-Chesa P, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001;20:6958–68.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  • Tommy Brown
    • 1
    • 4
  • Elin Sigurdson
    • 1
  • Andre Rogatko
    • 2
  • Dominique Broccoli
    • 3
  1. 1.Department of Surgical OncologyFox Chase Cancer CenterPhiladelphia
  2. 2.Department of BiostatisticsFox Chase Cancer CenterPhiladelphia
  3. 3.Department of Medical OncologyFox Chase Cancer CenterPhiladelphia
  4. 4.Philadelphia

Personalised recommendations